Maravai LifeSciences Holdings (MRVI) EPS Loss Deepens Narrative On Persistent Profitability Concerns

Maravai LifeSciences Holdings (MRVI) closed out FY 2025 with Q4 revenue of US$49.9 million and a basic EPS loss of US$0.25, alongside a trailing twelve month basic EPS loss of US$0.91 on revenue of US$185.7 million, keeping profitability squarely in focus for investors following the story. Over recent periods, quarterly revenue has ranged from US$41.6 million to US$49.9 million while basic EPS losses have moved between US$0.18 and US$0.27 per quarter, setting a clear backdrop of ongoing net losses that puts the spotlight on margins and the path to earnings stability.

See our full analysis for Maravai LifeSciences Holdings.

With the headline numbers on the table, the next step is to line these results up against the prevailing narratives about Maravai, highlighting where the data supports the story and where it raises new questions for investors.

See what the community is saying about Maravai LifeSciences Holdings

Losses remain heavy at US$130.8 million over the year

• On a trailing 12 month basis, Maravai reported revenue of US$185.7 million against a net loss of US$130.8 million, with basic EPS at a loss of US$0.91, pointing to a business that is still some distance from breakeven.
• Bears argue that persistent losses and the roughly 56.2% yearly growth in net losses over five years highlight profit risk, and the current figures do line up with that concern:
  • Quarterly net losses in FY 2025 ranged from US$25.6 million to US$39.6 million, so there is no clear signal yet of a sustained improvement in profitability.
  • Analysts do not forecast profitability over the next three years, which is consistent with trailing EPS staying in loss territory at US$0.91 per share over the last 12 months.

Skeptics point to these recurring losses and question how long the story can rely on cost cutting and revenue growth hopes before a clear profit path appears. 🐻 Maravai LifeSciences Holdings Bear Case

7.5% revenue growth trails wider US market

• Revenue grew about 7.5% over the last 12 months to US$185.7 million, which is below the cited US market growth rate of 11.4% per year, and quarterly revenue during FY 2025 moved in a fairly tight band between US$41.6 million and US$49.9 million.
• Supporters of the bullish narrative lean on future growth in biologics safety testing and nucleic acid products, and the current numbers give a mixed read on that hope:
  • The 7.5% revenue growth rate is positive, yet it trails the broader market, which challenges the idea that Maravai is already outgrowing peers today.
  • At the same time, the presence of multiple analyst narratives targeting revenue in the US$230 million to US$250 million range over the next few years suggests bulls are leaning on new products and geographies rather than recent growth alone.

Bulls see today’s modest 7.5% growth as a base, not a ceiling, and argue that the real story sits in the projected ramp from newer platforms and international customers. 🐂 Maravai LifeSciences Holdings Bull Case

P/S at 3.1x with DCF fair value below price

• Maravai trades on a P/S of 3.1x, below a peer average of 9x and slightly below the US Life Sciences industry at 3.4x, while a DCF fair value of US$3.59 sits under the current share price of US$3.94.
• Consensus narrative talks about valuation tension, and the current data captures that push and pull clearly:
  • The lower P/S multiple versus peers points to some relative valuation support on a sales basis, which some investors may see as room for upside if revenue or margins improve from here.
  • By contrast, the share price sitting above the DCF fair value, together with ongoing losses of US$130.8 million over the last year, aligns with the view that the stock is not clearly cheap when cash flows are the focus.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Maravai LifeSciences Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

See What Else Is Out There

Maravai is still posting sizeable annual losses, trailing wider US revenue growth and trading above its DCF fair value. Together, these factors highlight profit, growth and valuation pressure.

If those issues make you cautious here, it is worth widening your search to companies that look cheaper on quality metrics using the 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com